Deficiency of sphingomyelin synthase 2 prolongs survival by the inhibition of lymphoma infiltration through ICAM-1 reduction.
Animals
Blotting, Western
Cell Line, Tumor
Chromatography, Liquid
Disease Models, Animal
Flow Cytometry
Glucosyltransferases
/ metabolism
Immunohistochemistry
Intercellular Adhesion Molecule-1
/ genetics
Liver
/ drug effects
Mice
Mice, Knockout
Mice, Mutant Strains
RNA, Messenger
/ genetics
Tandem Mass Spectrometry
Transferases (Other Substituted Phosphate Groups)
/ genetics
Tumor Necrosis Factor-alpha
/ pharmacology
ICAM-1
SMS2
infiltration
malignant lymphoma
sphingomyelin
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
16
07
2019
revised:
10
12
2019
accepted:
23
12
2019
pubmed:
24
1
2020
medline:
26
1
2021
entrez:
24
1
2020
Statut:
ppublish
Résumé
The tumor microenvironment (TME) formation involving host cells and cancer cells through cell adhesion molecules (CAMs) is essential for the multiple steps of cancer metastasis and growth. Sphingomyelin synthase 2 (SMS2) is involved in inflammatory diseases such as obesity and diabetes mellitus by regulation of the SM/ceramide balance. However, the involvement of SMS2 in TME formation and metastasis is largely unknown. Here, we report that SMS2-deficient (SMS2-KO) mice show suppressed the EL4 cell infiltration to liver and prolonged survival time. ICAM-1 was identified as a candidate for the inhibition of TME formation in immortalized mouse embryonic fibroblasts (tMEFs) from mRNA array analysis for CAMs. Reduced SM/ceramide balance in SMS2-KO tMEFs suppressed the attachment of EL4 cells through transcriptional reduction of ICAM-1 by the inhibition of NF-κB activation. TNF-α-induced NF-κB activation and subsequent induction of ICAM-1 were suppressed in SMS2-KO tMEFs but restored by SMS2 re-introduction. In the EL4 cell infiltration mouse model, EL4 injection increased ICAM-1 expression in WT liver but not in SMS2-KO mouse liver. Therefore, inhibition of SMS2 may be a therapeutic target to suppress the infiltration of malignant lymphoma.
Identifiants
pubmed: 31970839
doi: 10.1096/fj.201901783RR
doi:
Substances chimiques
Icam1 protein, mouse
0
RNA, Messenger
0
Tumor Necrosis Factor-alpha
0
Intercellular Adhesion Molecule-1
126547-89-5
Glucosyltransferases
EC 2.4.1.-
ceramide glucosyltransferase
EC 2.4.1.80
Transferases (Other Substituted Phosphate Groups)
EC 2.7.8.-
Sgms2 protein, mouse
EC 2.7.8.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3838-3854Informations de copyright
© 2020 Federation of American Societies for Experimental Biology.
Références
Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239-252.
Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840.
Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett. 2015;368:7-13.
Harjunpaa H, Llort Asens M, Guenther C, Fagerholm SC. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front Immunol. 2019;10:1078.
Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169:203-214.
Lee IT, Yang CM. Inflammatory signalings involved in airway and pulmonary diseases. Mediators Inflamm. 2013;2013:791231.
Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
Burke-Gaffney A, Hellewell PG. Tumour necrosis factor-alpha-induced ICAM-1 expression in human vascular endothelial and lung epithelial cells: modulation by tyrosine kinase inhibitors. Br J Pharmacol. 1996;119:1149-1158.
Woo CH, Lim JH, Kim JH. VCAM-1 upregulation via PKCdelta-p38 kinase-linked cascade mediates the TNF-alpha-induced leukocyte adhesion and emigration in the lung airway epithelium. Am J Physiol Lung Cell Mol Physiol. 2005;288:L307-L316.
Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol. 2016;34:4270-4276.
Taniguchi M, Okazaki T. The role of sphingomyelin and sphingomyelin synthases in cell death, proliferation and migration-from cell and animal models to human disorders. Biochim Biophys Acta. 2014;1841:692-703.
Kitatani K, Taniguchi M, Okazaki T. Role of sphingolipids and metabolizing enzymes in hematological malignancies. Mol Cells. 2015;38:482-495.
Shakor AB, Taniguchi M, Kitatani K, et al. Sphingomyelin synthase 1-generated sphingomyelin plays an important role in transferrin trafficking and cell proliferation. J Biol Chem. 2011;286:36053-36062.
Asano S, Kitatani K, Taniguchi M, et al. Regulation of cell migration by sphingomyelin synthases: sphingomyelin in lipid rafts decreases responsiveness to signaling by the CXCL12/CXCR4 pathway. Mol Cell Biol. 2012;32:3242-3252.
Taniguchi M, Tasaki T, Ninomiya H, et al. Sphingomyelin generated by sphingomyelin synthase 1 is involved in attachment and infection with Japanese encephalitis virus. Sci Rep. 2016;6:37829.
Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139-150.
Trayssac M, Hannun YA, Obeid LM. Role of sphingolipids in senescence: implication in aging and age-related diseases. J Clin Invest. 2018;128:2702-2712.
Taniguchi M, Kitatani K, Kondo T, et al. Regulation of autophagy and its associated cell death by "sphingolipid rheostat": reciprocal role of ceramide and sphingosine 1-phosphate in the mammalian target of rapamycin pathway. J Biol Chem. 2012;287:39898-39910.
Mitsutake S, Zama K, Yokota H, et al. Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes. J Biol Chem. 2011;286:28544-28555.
Hailemariam TK, Huan C, Liu J, et al. Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation. Arterioscler Thromb Vasc Biol. 2008;28:1519-1526.
Liu J, Huan C, Chakraborty M, et al. Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice. Circ Res. 2009;105:295-303.
Zhang Y, Dong J, Zhu X, Wang W, Yang Q. The effect of sphingomyelin synthase 2 (SMS2) deficiency on the expression of drug transporters in mouse brain. Biochem Pharmacol. 2011;82:287-294.
Gowda S, Yeang C, Wadgaonkar S, et al. Sphingomyelin synthase 2 (SMS2) deficiency attenuates LPS-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2011;300:L430-L440.
Fan Y, Shi F, Liu J, et al. Selective reduction in the sphingomyelin content of atherogenic lipoproteins inhibits their retention in murine aortas and the subsequent development of atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:2114-2120.
Ohnishi T, Hashizume C, Taniguchi M, et al. Sphingomyelin synthase 2 deficiency inhibits the induction of murine colitis-associated colon cancer. FASEB J. 2017;31:3816-3830.
Matsuura K, Suetsugu A, Satake T, et al. Choline-deficient-diet decreases fibroblasts in the circulating tumor cell (CTC) microenvironment. Anticancer Res. 2019;39:4061-4064.
Nakamura M, Suetsugu A, Hasegawa K, et al. Choline-deficient-diet-induced fatty liver is a metastasis-resistant microenvironment. Anticancer Res. 2017;37:3429-3434.
Matsumoto T, Suetsugu A, Hasegawa K, et al. Color-coded imaging of syngeneic orthotopic malignant lymphoma interacting with host stromal cells during metastasis. Anticancer Res. 2016;36:1473-1478.
Yano M, Watanabe K, Yamamoto T, et al. Mitochondrial dysfunction and increased reactive oxygen species impair insulin secretion in sphingomyelin synthase 1-null mice. J Biol Chem. 2011;286:3992-4002.
Ogiso H, Taniguchi M, Okazaki T. Analysis of lipid-composition changes in plasma membrane microdomains. J Lipid Res. 2015;56:1594-1605.
Zhang Z, Knoepp SM, Ku H, et al. Differential expression of FAK and Pyk2 in metastatic and non-metastatic EL4 lymphoma cell lines. Clin Exp Metastasis. 2011;28:551-565.
Ding L, Sunamura M, Kodama T, et al. In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells. Br J Cancer. 2001;85:431-438.
Liu J, Zhang H, Li Z, et al. Sphingomyelin synthase 2 is one of the determinants for plasma and liver sphingomyelin levels in mice. Arterioscler Thromb Vasc Biol. 2009;29:850-856.
Li Y, Dong J, Ding T, et al. Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-activated receptor gamma2 suppression. Arterioscler Thromb Vasc Biol. 2013;33:1513-1520.
Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392-401.
Matsumoto T, Suetsugu A, Shibata Y, et al. A Color-coded imageable syngeneic mouse model of stromal-cell recruitment by metastatic lymphoma. Anticancer Res. 2015;35:4647-4654.
Ueda Y, Ishiwata T, Shinji S, et al. In vivo imaging of T cell lymphoma infiltration process at the colon. Sci Rep. 2018;8:3978.
Aoudjit F, Potworowski EF, Springer TA, St-Pierre Y. Protection from lymphoma cell metastasis in ICAM-1 mutant mice: a posthoming event. J Immunol. 1998;161:2333-2338.
Bertolino P, Schrage A, Bowen DG, et al. Early intrahepatic antigen-specific retention of naive CD8+ T cells is predominantly ICAM-1/LFA-1 dependent in mice. Hepatology. 2005;42:1063-1071.
Kanwar JR, Berg RW, Yang Y, et al. Requirements for ICAM-1 immunogene therapy of lymphoma. Cancer Gene Ther. 2003;10:468-476.
Canel M, Serrels A, Frame MC, Brunton VG. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci. 2013;126:393-401.
Bevilacqua MP, Nelson RM. Selectins. J Clin Invest. 1993;91:379-387.
Sakamoto H, Yoshida T, Sanaki T, et al. Possible roles of long-chain sphingomyelines and sphingomyelin synthase 2 in mouse macrophage inflammatory response. Biochem Biophys Res Commun. 2017;482:202-207.
Clarke CJ, Truong TG, Hannun YA. Role for neutral sphingomyelinase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2. J Biol Chem. 2007;282:1384-1396.
Alvarez SE, Harikumar KB, Hait NC, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010;465:1084-1088.
Rosette C, Roth RB, Oeth P, et al. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis. 2005;26:943-950.
Kotteas EA, Boulas P, Gkiozos I, Tsagkouli S, Tsoukalas G, Syrigos KN. The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: implications for disease progression and prognosis. Anticancer Res. 2014;34:4665-4672.
Benedicto A, Romayor I, Arteta B. Role of liver ICAM-1 in metastasis. Oncol Lett. 2017;14:3883-3892.
Fernandez-Garcia P, Rossello CA, Rodriguez-Lorca R, et al. The opposing contribution of SMS1 and SMS2 to glioma progression and their value in the therapeutic response to 2OHOA. Cancers. 2019;11:88.